Drug Profile


Alternative Names: AZD-0914; ETX0914

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Antibacterials; Ketones; Oxazines; Oxazolidinones; Pyrimidines; Quinolines; Spiro compounds
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Gonorrhoea

Most Recent Events

  • 26 Oct 2016 Efficacy data from a phase II trial in Gonorrhea presented at the IDWeek 2016 (IDW-2016)
  • 21 Sep 2016 Efficacy and adverse events data from a phase II trial in Gonorrhea released by Entasis
  • 08 Jul 2015 ETX 0914 is available for licensing as of 08 Jul 2015. http://www.entasistx.com/partnering/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top